Merck & Co., Inc.: PharmaVitae Profile - Market Research Reports

Contents:

CHAPTER 1 EXECUTIVE SUMMARY 2
Key findings 2
Historical and forecast ethical sales performance 3
Therapeutic strategy 4
Launch and expiry outlook 7
Externalization, geographic and molecule type strategies 10
Externalization strategy 11
Geographic strategy 12
Molecule type strategy 12
SWOT analysis 13
Strengths 13
Weaknesses 14
Opportunities 15
Threats 16
CHAPTER 2 CORPORATE HISTORY 21
Key findings 21
Background 22
Key corporate developments 22
Merck & Co. global restructuring plan: December 2005 - highlights 23
M&A history 24
Divestments 24
Acquisitions 24
GlycoFi 25
Abmaxis 25
Sirna Therapeutics 26
NovaCardia 26
CHAPTER 3 HISTORICAL PERFORMANCE 27
Key findings 27
Introduction 28
Revenue and growth rate analysis, 2001-06 28
Revenue and growth rate vs. peer set 29
Product analysis, 2001-06 31
Growth drivers 31
Singulair 31
Zetia/Vytorin 32
Fosamax 32
Growth resistors 32
Zocor 32
Vioxx 32
Operating revenue and cost analysis, 2001-06 33
Operating revenue/cost analysis 34
CHAPTER 4 FORECAST PERFORMANCE 36
Key findings 36
Introduction 37
Revenue and growth rate, 2006-12 37
Product analysis, 2006-12 39
Growth drivers 44
Januvia 44
Zetia/Vytorin 45
Gardasil 45
Others 46
Growth resistors 46
Zocor 46
Fosamax 47
Cozaar/Hyzaar 47
Therapy area analysis, 2006-12 49
Endocrine, metabolic and genetic disorders 52
Infectious diseases 52
Oncology 53
Cardiovascular & hematology 53
Musculoskeletal 53
Therapy area focus 54
Launches and expiries analysis, 2006-12 59
Launch portfolio 60
Core portfolio 64
Expiry portfolio 66
Launch/core/expiry configuration 68
Externalization analysis, 2006-12 72
Geographic analysis, 2006-12 77
Molecule type analysis, 2006-12 81
CHAPTER 5 KEY PRODUCTS AND COMPETITORS 87
Key findings 87
Overview 88
Cardiovascular 89
Zetia/Vytorin 89
Overview 89
Sales forecast 90
Newsflow 91
MK-0524B 96
Overview 96
Sales forecast 97
Newsflow 97
Cozaar/Hyzaar 99
Overview 99
Sales forecast 100
Newsflow 101
Zocor 102
Overview 102
Sales forecast 103
Newsflow 103
Respiratory 106
Singulair 106
Overview 106
Sales forecast 107
Newsflow 107
Endocrine, metabolic & genetic disorders 111
Januvia 111
Overview 111
Sales forecast 112
Newsflow 112
Oncology 116
Gardasil 116
Overview 116
Sales forecast 117
Newsflow 117
Musculoskeletal 123
Fosamax 123
Overview 123
Sales forecast 124
Newsflow 124
CHAPTER 6 APPENDIX 127
IMS vs. company-reported data reconciliation 127
Abbreviations 130
List of Tables
Table 1: Peer set overview 29
Table 2: Operating revenue/cost analysis ($m), 2001-06 33
Table 3: Operating cost ratio analysis (% of total revenues), 2001-06 34
Table 4: Product portfolio overview, sales ($m), 2006-12 39
Table 5: Therapy area overview, sales ($m), 2006-12 49
Table 6: Launch portfolio overview, sales ($m), 2006-12 60
Table 7: Core portfolio overview, sales ($m), 2006-12 64
Table 8: Expiry portfolio overview, sales ($m), 2006-12 66
Table 9: Externally developed portfolio ($m), 2006-12 72
Table 10: Molecule type overview, sales ($m), 2006-12 81
Table 11: Key products overview 88
Table 12: Zetia/Vytorin: overview 89
Table 13: Zetia/Vytorin: sales forecast ($m), 2006-12 90
Table 14: Zetia/Vytorin: news flow 91
Table 15: Antidyslipidemic market overview, 7MM sales ($m), 2006 94
Table 16: MK-0524B: overview 96
Table 17: MK-0524B: sales forecast ($m), 2006-12 97
Table 18: MK-0524B: news flow 97
Table 19: Cozaar/Hyzaar: overview 99
Table 20: Cozaar: sales forecast ($m), 2006-12 100
Table 21: Hyzaar: sales forecast ($m), 2006-12 100
Table 22: Cozaar/Hyzaar: news flow 101
Table 23: Zocor: overview 102
Table 24: Zocor: sales forecast ($m), 2006-12 103
Table 25: Zocor: news flow 103
Table 26: Singulair: overview 106
Table 27: Singulair: sales forecast ($m), 2006-12 107
Table 28: Singulair: news flow 107
Table 29: Januvia: overview 111
Table 30: Januvia: sales forecast ($m), 2006-12 112
Table 31: Januvia: news flow 112
Table 32: Gardasil: overview 116
Table 33: Gardasil: sales forecast ($m), 2006-12 117
Table 34: Gardasil: news flow 117
Table 35: Fosamax: overview 123
Table 36: Fosamax: sales forecast ($m), 2006-12 124
Table 37: Fosamax: news flow 124
List of Figures
Figure 1: Historical and forecast ethical sales performance (% CAGR), Merck & Co. and Big Pharma peer set 3
Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006 5
Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Merck & Co. 8
Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 9
Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006 10
Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012 11
Figure 7: SWOT analysis of Merck & Co. 13
Figure 8: Revenue & growth rate (ethical sales) ($m), 2001-06 28
Figure 9: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06 30
Figure 10: Growth drivers/resistor products of historical revenue performance ($m), 2001-06 31
Figure 11: Operating revenue/cost analysis ($m), 2001-06 34
Figure 12: Operating cost ratio analysis (% of total revenues), 2001-06 35
Figure 13: Ethical revenue ($m) and growth rate (%), 2006-12 38
Figure 14: Top five products by sales ($m), 2006 41
Figure 15: Top five products by sales ($m), 2012 43
Figure 16: Growth drivers and resistors by product, 2006-12 44
Figure 17: Key strategic products, sales ($m), 2006-12 48
Figure 18: Ethical sales by therapy area ($m), 2006-12 51
Figure 19: Growth drivers and resistors by therapy area ($m), 2006-12 52
Figure 20: Ethical sales by therapy area (%), 2006-12 54
Figure 21: Therapy area focus compared with peer set (% total ethical sales), 2006 55
Figure 22: Therapy area focus compared with peer set (% total ethical sales), 2012 58
Figure 23: Launch schedule, sales ($m), 2006-12 61
Figure 24: Core products sales growth ($m), 2006-12 65
Figure 25: Expiry schedule, sales ($m), 2006-12 67
Figure 26: Launch, core and expiry, sales ($m), 2006-12 68
Figure 27: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Merck & Co. 70
Figure 28: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 71
Figure 29: Externalization dependency, sales ($m), 2006-12 73
Figure 30: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12 74
Figure 31: Externalization dependency vs. peer set, % total sales, 2006 75
Figure 32: Externalization dependency vs. peer set, % total sales, 2012 76
Figure 33: Geographical sales breakdown ($m), 2006-12 77
Figure 34: Growth drivers and resistors by geography, sales ($m), 2006-12 78
Figure 35: US dependency vs. peer set, % total sales, 2006 79
Figure 36: US dependency vs. peer set, % total sales, 2012 80
Figure 37: Molecule type sales breakdown ($m), 2006-12 82
Figure 38: Growth drivers and resistors by molecule type, sales ($m), 2006-12 84
Figure 39: Biologics dependency vs. peer set, % total sales, 2006 85
Figure 40: Biologics dependency vs. peer set, % total sales, 2012 86
Figure 41: Top five antidyslipidemic drug quarterly sales ($m), 7MM, 2006 93
Figure 42: IMS vs. company-reported ethical sales discrepancy ($m), 2006 128
Figure 43: IMS vs. company-reported ethical sales forecast growth rates (%), 2006-12 129